Loading data for ASND — first visit, this takes a few seconds.

Alerta

Ascendis Pharma A/S (ASND)

NasdaqGS: ASND · Precio en tiempo real · USD

259.62

+10.77 (4.33%)

Al cierre: Aug 19, 2026, 8:00 PM

238.59

-8.10%

Fuera de horario: 5:07 PM

4.33% (1D)

No hay datos disponibles

Precio de compra	235.1
Capitalización de mercado	17.03B
Ingresos (TTM)	1.05B
Beneficio neto (TTM)	741.76M
Beta	n/a
EPS (TTM)	12.96
Ratio PER (TTM)	20.03
Adelante PE	27.47
P/B (TTM)	10.25
P/S (TTM)	16.26
Earnings Date	Apr 30, 2026

Precio de venta	273.78
Volumen	535,689
Volumen medio (20D)	677,188
Abierto	255.00
Anterior Cerrar	248.85
Rango del día	251.11 - 261.61
Rango de 52 semanas	186.05 - 282.15
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ASND

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endo...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jan 28, 2015

Empleados 1,189

Bolsa de Valores NasdaqGS

Símbolo bursátil ASND

Sitio web https://ascendispharma.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Ascendis Pharma A/S fueron 720.13M, un aumento de 98.03% en comparación con 363.64M del año anterior. Las ganancias fueron -228.03M, una disminución de -39.69%.

Estados financieros

Sorpresa de resultados

Ascendis Pharma A/S ha publicado sus resultados trimestrales en Aug 13, 2026:

Ingresos de $246.6M falla las estimaciones por $0, con 144.27% Crecimiento interanual.

EPS de 0.9 supera las estimaciones en 0.13, con 240.63% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Ascendis Pharma A/S publique sus resultados el Apr 30, 2026, después del cierre del mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

5 días hace · MT Newswires

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of

5 días hace · GuruFocus.com

Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Revenue Doubles to EUR315 ...

Ascendis Pharma AS (ASND) reports record Q2 2026 results with product revenue more than doubling year-over-year, driven by strong YORVIPATH and YUVIWEL performance.

6 días hace · MT Newswires

European Equities Traded in the US Rise in Thursday Trading

European equities traded in the US as American depositary receipts were higher late Thursday morning

6 días hace · MarketBeat

Ascendis Pharma A/S Q2 Earnings Call Highlights

Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based therapi...

1 semana hace · MT Newswires

European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

European equities traded in the US as American depositary receipts were heading higher late Thursday

Página 1 de 2

Ascendis Pharma A/S (ASND)